Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Ruxolitinib shows promise in myeloma

James Berenson • 14 Sep 2019
IMW 2019
Multiple Myeloma Lenalidomide Methylprednisolone Ruxolitinib

The Phase I study (NCT03110822) of ruxolitinib in combination with lenalidomide and methylprednisolone shows promise in patients with high-risk R/R myeloma, as discussed by James Berenson, MD, from The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA. Dr Berenson was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from James Berenson

1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
1:08
Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study
James Berenson • 11 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals